Another drug that target HDAC, Belinostat, in the Phase I/II trial (NCT00321594), explores the side effects and best dose of the drug in treating patients with HCC that cannot be removed by surgery. This evidence concerns the gene HDAC9 and hepatocellular carcinoma.